We would love to connect with you during the DIA and discuss how we can support you to optimise your path to market approval.

Working together we can:

  • Accelerate your drug development program to reduce your time to approval
  • Optimise the management of the regulatory process to provide accurate and predictable outcomes
  • Reduce your risks and increase the probability of gaining Market Authorization

Don't miss our  great speakers sharing their knowledge in different forums throughout the conference:

Dr Steffen Thirstrup - NDA Advisory Board Director & John Ellis, Communications Coach, PharmApprove, NDA Group

A tutorial on Tuesday, June 22 • 09:30 – 12:30 EDT – Tutorial (Short Course)

025A: #025A: Optimizing your interaction with EU Regulatory Authorities: How to Prepare and Perform

Shelley Gandhi, Patient Safety & Pharmacovigilance Director, NDA Group

A session on 17th June • 12:00 - 13:00 EDT  On-Demand and will be available anytime for viewing

OD: Safety Compliance

Clinical Trial Regulation is an Opportunity to Revisit Compliance at the Pharmacovigilance and GCP Interface

Dr Brian Edwards, Principal Consultant, NDA Group

Two Sessions - Semi-Live and will include live Q&A with our Speakers.

Monday, June 28 • 16:00 - 17:00 EDT
#SL: A Journey of Interdisciplinary Collaboration to Improve Safety Evaluation in Drug Development

Tuesday, June 29 • 14:00 - 15:00 EDT

#L: Systems Thinking: A better Way of Safety Management Planning

Click here to download the full programme.


To book a meeting with one our team simply
contact us meet-us@ndareg.com


Dr Steffen Thirstrup


John Ellis

Communications Coach, PharmApprove

Read More

Shelley Ghandi

Patient Safety & Pharmacovigilance Director

Read More


Dr Brian Edwards


Stay up to date

Contact us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World

  • This field is for validation purposes and should be left unchanged.